Author

K. F. Chung

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. B. Tobin· 1 shared A. G. Alharbi· 1 shared A. James· 1 shared C. Burke· 1 shared C. Churchward· 1 shared C. Donovan· 1 shared C. E. Brightling· 1 shared C. H. Wiegman· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. B. Tobin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genomic and ecologic characteristics of the airway microbial-mucosal complex

L. Cuthbertson, U. Lober, J. S. Ish-Horowicz, C. N. McBrien, C. Churchward, J. C. Parker, M. T. Olanipekun, C. Burke, O. O'Carroll, J. Faul, G. A. Davies, K. E. Lewis, J. M. Hopkin, J. Creaser-Thomas, R. Ghosal, , W. O. C. Cookson

The paper characterizes the genomic and ecological features of the airway microbial-mucosal complex, identifying novel bacteria and functional pathways linked to lung diseases.

bioRxiv · Sep 8, 2022 · PreprintMicrobiology

Pathophysiological regulation of lung function by the free fatty acid receptor FFA4

A. B. Tobin, R. Prihandoko, D. Kaur, C. H. Wiegman, E. Alvarez-Curto, C. Donovan, L. Chachi, T. Ulven, M. R. Tyas, E. Euston, Z. Dong, A. G. Alharbi, R. Kim, J. G. Lowe, P. M. Hansbro, , G. Milligan

This study shows that activating FFA4 reduces airway resistance in mouse models of inflammation and human lung tissue, suggesting it could be a therapeutic target for asthma and COPD.

bioRxiv · May 18, 2020Pharmacology & Toxicology